Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy aims to stall prostate cancer spread Results expected Sep 2027 (estimated)
-
Can gentler therapy beat harsh chemo for tough leukemia?
Disease control Recruiting nowThis phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…
Phase 3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo therapy aims to stall prostate cancer spread
Disease control Recruiting nowThis phase II trial tests whether adding a radioactive drug called Lu-PSMA to precise radiation therapy can better control prostate cancer that has spread to just 1-3 spots. About 70 men with hormone-sensitive prostate cancer will be randomly assigned to get radiation alone or ra…
Phase 2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Massive study to track what happens when AML comes back
Knowledge-focused Recruiting nowThis observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC